Su Hua-Poo, Golden Joseph W, Gittis Apostolos G, Hooper Jay W, Garboczi David N
Structural Biology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12441 Parklawn Drive, Rockville, MD 20852, USA.
Virology. 2007 Nov 25;368(2):331-41. doi: 10.1016/j.virol.2007.06.042. Epub 2007 Aug 3.
Medical countermeasures to prevent or treat smallpox are needed due to the potential use of poxviruses as biological weapons. Safety concerns with the currently available smallpox vaccine indicate a need for research on alternative poxvirus vaccine strategies. Molecular vaccines involving the use of proteins and/or genes and recombinant antibodies are among the strategies under current investigation. The poxvirus L1 protein, encoded by the L1R open reading frame, is the target of neutralizing antibodies and has been successfully used as a component of both protein subunit and DNA vaccines. L1-specific monoclonal antibodies (e.g., mouse monoclonal antibody mAb-7D11, mAb-10F5) with potent neutralizing activity bind L1 in a conformation-specific manner. This suggests that proper folding of the L1 protein used in molecular vaccines will affect the production of neutralizing antibodies and protection. Here, we co-crystallized the Fab fragment of mAb-7D11 with the L1 protein. The crystal structure of the complex between Fab-7D11 and L1 reveals the basis for the conformation-specific binding as recognition of a discontinuous epitope containing two loops that are held together by a disulfide bond. The structure of this important conformational epitope of L1 will contribute to the development of molecular poxvirus vaccines and also provides a novel target for anti-poxvirus drugs. In addition, the sequence and structure of Fab-7D11 will contribute to the development of L1-targeted immunotherapeutics.
由于痘病毒可能被用作生物武器,因此需要采取预防或治疗天花的医学对策。目前可用的天花疫苗存在安全问题,这表明需要研究替代痘病毒疫苗策略。涉及使用蛋白质和/或基因以及重组抗体的分子疫苗是目前正在研究的策略之一。由L1R开放阅读框编码的痘病毒L1蛋白是中和抗体的靶标,已成功用作蛋白质亚基疫苗和DNA疫苗的组成部分。具有强中和活性的L1特异性单克隆抗体(例如,小鼠单克隆抗体mAb-7D11、mAb-10F5)以构象特异性方式结合L1。这表明分子疫苗中使用的L1蛋白的正确折叠将影响中和抗体的产生和保护作用。在此,我们将mAb-7D11的Fab片段与L1蛋白共结晶。Fab-7D11与L1之间复合物晶体结构揭示了构象特异性结合的基础,即识别由二硫键连接在一起的两个环组成的不连续表位。L1这一重要构象表位的结构将有助于分子痘病毒疫苗的开发,也为抗痘病毒药物提供了新靶点。此外,Fab-7D11的序列和结构将有助于开发针对L1的免疫疗法。